Search the Newsreel

Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates

Lucid Diagnostics Inc. (LUCD) reported a wider-than-expected Q2 loss of $0.06 per share, missing the Zacks Consensus Estimate of a $0.04 loss, and its revenues of $1.47 million also fell short of estimates. The company has underperformed the S&P 500 year-to-date, and its shares …

Earnings call transcript: Lucid Diagnostics posts Q2 2026 revenue beat, shares slip

Lucid Diagnostics (LUCD) reported a Q2 2026 revenue beat of $1.47 million, surpassing expectations by 2.8%, though shares slipped slightly. The company matched Wall Street forecasts with a loss of 6 cents per share, and its EsoGuard test volume remained within target. Management highlighted …

Lucid Diagnostics earnings matched, revenue topped estimates

Lucid Diagnostics Non-GAAP EPS of -$0.06 misses by $0.01, revenue of $1.47M misses by $0.46M

* Lucid Diagnostics press release [https://seekingalpha.com/pr/20618076-lucid-diagnostics-provides-business-update-and-reports-second-quarter-2026-financial-results] (LUCD [https://seekingalpha.com/symbol/LUCD]): Q2 Non-GAAP EPS of -$0.06 misses by $0.01. * Revenue of $1.47M (+26.7% Y/Y) misses by $0.46M. * Processed 2,770 EsoGuard tests * Lucid had cash and cash equivalents of $33.4 million as of June 30, …

Lucid Diagnostics Secures EsoGuard Policy Adopted by Health Plans

Earnings To Watch: Lucid Diagnostics Inc (LUCD) Q2 2026 -- GF Value Sees 5% Upside

Lucid Diagnostics Inc (LUCD) is scheduled to release its Q2 2026 earnings on August 13, 2026, with revenue estimates at $1.44 million and earnings at $-0.07 per share. Analysts' revenue estimates for the full year 2026 and 2027 have declined, as have earnings estimates …

Lucid Diagnostics (NASDAQ:LUCD) Issues Earnings Results, Misses Estimates By $0.04 EPS

Lucid Diagnostics (NASDAQ:LUCD) reported a Q2 loss of $0.08 per share, missing analyst estimates by $0.04, despite revenue of $1.47 million which slightly exceeded expectations. Shares rose 1.9% following the announcement but remain near their 12-month low. Insider buying was noted, with Director Dennis …

Lucid Diagnostics (LUCD) Releases Q2 2026 Earnings: Revenue Up 26.7% but Losses Continue

Lucid Diagnostics (LUCD) reported a 26.7% increase in Q2 2026 revenue, reaching $1.5 million, which slightly exceeded analyst expectations. Despite this top-line growth, the company continued to post significant losses, with a net loss of $14.7 million. Insider trading activity shows one purchase in …

$LUCD Q2 '26 Earnings Results & Recap

Lucid Diagnostics (NASDAQ: LUCD) grows revenue but warns on going concern, debt load

Lucid Diagnostics 2026: Revenue $1.47M, EPS ($0.08) — 10-Q Summary

Lucid Diagnostics Inc. reported its Q2 2026 financial results, showing revenue of $1.47 million and a net loss of ($14.72 million), resulting in a diluted loss per share of ($0.08). The company experienced increased EsoGuard test volume, expanded commercialization efforts, secured positive payer access …

Lucid Diagnostics Inc expected to post a loss of 7 cents a share - Earnings Preview

Lucid Diagnostics Inc is anticipated to report a loss of 7 cents per share in its upcoming earnings announcement. This preview indicates the company's expected financial performance for the period.

Lucid Diagnostics Inc (LUCD) Earnings Forecast: Future EPS & Revenue Growth Estimates

Price to sales forward of Lucid Diagnostics Inc. – NASDAQ:LUCD

This page displays the "Price to sales forward" financial metric for Lucid Diagnostics Inc. (NASDAQ: LUCD). It indicates that the market is closed, with no trades currently. The information is provided by TradingView, with market data from ICE Data Services and reference data from …

Lucid Diagnostics Inc (LUCD) Stock News Today

This page provides an overview of Lucid Diagnostics Inc (LUCD) stock news, including current trading information and a note that more news is coming soon. The stock is currently trading at 0.953 USD, down 0.05%, with a market cap of 124.88M. The article is …

Lucid Diagnostics Inc (LUCD) News, Articles, Events & Latest Updates

This article provides a compilation of recent news and updates regarding Lucid Diagnostics Inc. (LUCD), including coverage policies for its EsoGuard test, upcoming investor conference participations, and quarterly earnings reports from related companies. It also mentions a price target reduction for LUCD despite expected …

Lucid Diagnostics (LUCD) Projected to Announce Quarterly Earnings on Thursday

Lucid's EsoGuard Is the Only Esophageal Precancer Test Meeting Coverage Criteria

Lucid Diagnostics (Nasdaq: LUCD) announced that Concert, a healthcare technology company recently acquired by Lyric, issued a positive commercial coverage policy for its EsoGuard Esophageal DNA Test, effective July 2026. This policy deems EsoGuard medically necessary for non-invasive screening of esophageal precancer and cancer …

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

Lucid Diagnostics Inc. announced that Concert, a healthcare technology company, has issued a positive coverage policy for its EsoGuard® Esophageal DNA Test. This policy, effective July 2026, recognizes EsoGuard as medically necessary for non-invasive screening of esophageal precancer and cancer in patients meeting ACG …

Lucid Diagnostics to Participate in Upcoming Investor Conferences

Lucid Diagnostics Inc. announced its participation in two upcoming investor conferences: the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, and the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. Management will hold 1x1 meetings and a …

Lucid Diagnostics Sets Boston Fireside Chat and Virtual Meetings

Lucid Diagnostics (Nasdaq: LUCD), a cancer prevention diagnostics company and subsidiary of PAVmed (Nasdaq: PAVM), announced its participation in two upcoming investor events. Management will attend the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on August 10, 2026, and host a fireside …

Lucid Diagnostics CEO and CFO to Discuss Operations Aug. 13

Lucid Diagnostics (Nasdaq: LUCD) will host a second quarter 2026 business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. CEO Lishan Aklog, M.D. and CFO Dennis McGrath will discuss business operations, growth strategy, and financial results. Investors can …

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Lucid Diagnostics (Nasdaq: LUCD) will host a business update conference call and webcast on Thursday, August 13, 2026, at 8:30 AM ET. Chairman and CEO Lishan Aklog, M.D., will provide a business update and discuss the company's operations and growth strategy, while CFO Dennis …

Lucid Diagnostics Inc (LUCD) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lucid Diagnostics Inc (LUCD), detailing its price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The stock's current price momentum score is 4.57, ranking 75th in its industry, trading between …

LUCD|Lucid Diagnostics Inc|Price:0.923|Chg%:+0.019

TradingKey provides a comprehensive stock analysis for Lucid Diagnostics Inc (LUCD), highlighting its "fairly valued" status with high institutional ownership and strong fundamentals despite recent weak stock market performance. The company, which specializes in medical diagnostics for esophageal precancer and cancer with products like …

Lucid Diagnostics Inc (LUCD) Institutional Confidence

Lucid Diagnostics Inc's (LUCD) institutional confidence score is 3.00, placing it 130th out of 199 in the Healthcare Equipment & Supplies industry. The institutional shareholding proportion has decreased by 30.84% quarter-over-quarter to 20.09%. James Simons is the largest institutional shareholder, holding 0.30% of outstanding …

Lucid Diagnostics Inc (LUCD) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides information about Lucid Diagnostics Inc (LUCD) dividends and stock splits, indicating that the company has not distributed any dividends over the past five years. It also includes current stock price data and market capitalization for LUCD, alongside general company information and …

Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives Average Recommendation of "Moderate Buy" from Analysts

Lucid Diagnostics Inc (LUCD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Lucid Diagnostics Inc (LUCD). It notes that relevant data regarding business segments and regional revenue by business has not been disclosed by the company yet. As of the last reported data, the United States accounted …

Lucid Diagnostics Market Sentiment

This article provides an overview of market sentiment signals for Lucid Diagnostics (LUCD), including analyst consensus, short interest, options flow, and insider activity. Analysts have a "Buy" consensus with an average price target of $4, and short interest is at 6.1%. The article also …

Lucid Diagnostics Inc (LUCD) Cash Flow

This article provides a detailed overview of Lucid Diagnostics Inc's (LUCD) cash flow statements, including operating, investing, and financing activities. It presents quarterly and annual financial data, allowing users to evaluate the company's financial soundness and stability. The article also includes FAQs explaining cash …

Lucid Diagnostics Inc (LUCD) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Lucid Diagnostics Inc (LUCD), noting its current valuation score of 8.75, which ranks 67th in the Healthcare Equipment & Supplies industry. The P/E ratio is reported as -2.69, having fluctuated significantly from its recent high and low. …